The results presented here demonstrate that a cisdiamminedichloroplatinum(II) (DDP)-resistant human ovarian-carcinoma cell line is also cross-resistant to the spermine analogue N 1 ,N 12 -bis(ethyl)spermine (BESPM). We report that C13\* cells, which are approximately 20-fold resistant to DDP, simila
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells
โ Scribed by Stephen C. Mann; Paul A. Andrews; Stephen B. Howell
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- French
- Weight
- 807 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
We have determined the effect of forskolin, an adenyl cy-Clare agonist, and 3-isobutyl-I-methylxanthine (IBMX), a phosphodiesterase inhibitor, on the accumulation and cytotoxicity of cisplatin (DDP) in 2008 human ovarian carcinoma cells. In DDP-sensitive 2008 cells, forskolin and IBMX caused 2. I -fold and 2.3-fold increases, respectively, in the short-term accumulation of DDP relative to untreated cells. The inactive analogue, I ,9-dideoxyforskolin, decreased DDP accumulation. Forskolin and IBMX also increased accumulation in A2780 cells. Neither forskolin nor IBMX had any effect on DDP accumulation in DDP-resistant 2008 cells. The effects were detectable as early as I min and persisted at 60 rnin. The concentrations for half-maximal stimulation of DDP accumulation were approximately 0.2 p~ for forskolin and 0.2 m M for IBMX. Forskolin caused marked increases in CAMP levels in both sensitive and resistant 2008 cells within I min, although there were differences in the subsequent time-courses of the response. Both 2008 cell types had identical CAMP-dependent protein kinase (PKA) activity. These results suggest that there is a target downstream of PKA that is an important participant in DDP accumulation, and that this target is defective or missing in DDP-resistant cells. Following a I-hr exposure to drugs, forskolin and IBMX at concentrations that were by themselves completely non-toxic increased the slopes of the clonogenic survival vs. DDP concentration curves in 2008 cells 1.9-fold and 3.3-fold, respectively. In DDPresistant 2008 cells, however, forskolin and IBMX increased the slopes only I .2 and 2.6-fold, respectively. These effects of forskolin and IBMX on DDP cytotoxicity did not directly correlate with the effects on the I-hr DDP accumulation which suggested that, in addition to modulating DDP accumulation, these agents increase the cytotoxicity of the intracellular platinum. The results indicate that modulation of cAMP levels can have important effects on DDP accumulation and cytotoxicity in 2008 cells and that these effects are significantly dimin- ished in DDP-resistant cells.
๐ SIMILAR VOLUMES
The ability of 12-0-tetradecanoylphorbol-I 3-acetate (TPA) and D,L-buthionine-S,R-sulphoximine (BSO) to modulate cisdiamminedichloroplatinum(ll) (CDDP) sensitivity was investigated in human ovarian cancer cell lines sensitive (KF) or with intrinsic resistance (KK and MH) to CDDP. The KK and MH cell
## Abstract This study was undertaken to elucidate the mechanism(s) of potentiation of cisplatin (CDDP) cytotoxicity by interferon ฮฑโ2a (IFN ฮฑโ2a) in human squamous carcinoma cell lines SCCโ25 and SCCโ4. IFN ฮฑโ2a treatment significantly increased the cytotoxicity of CDDP in both cell lines in a dos
Cytokines are directly cytotoxic to tumor cells in vitro and in vivo, and interleukinla (ILla) potentiates the cytotoxicity of a number of clinically active drugs in several human tumor cells, including carcinomas of the breast and ovary. In this study, we found that ILla potentiated the cytotoxicit
The combination of cis-diamminedichloroplatinum(ll) (CDDP) and 7-ethyl-I0-[4-( I -pipmidino)-I -piperidino]carbonyloxycamptothecin (CPT-I I), a topoisomerase-I inhibitor, has been shown to be synergistic in vitro and clinically active against several human cancers refractory to chemotherapy. To eluc